A systematic evaluation for the potential translation of CD166-related expression as a cancer biomarker

Introduction: Many basic studies have provided some evidences for the correlations of CD166 to cancer. However, along with the growing studies on the clinical values of CD166 in cancer areas, some controversial and inconclusive results were obtained. Areas covered: An appropriate query and collection of the published articles was conducted through search in PubMed and EMBASE database. A subsequent systematical and quantitative summary of CD166 related expression and cancer was conducted with meta-analysis to clarify its clinical significance for potential translation as cancer biomarkers. Expert commentary: The overall results suggested total CD166 correlated to cancer risk, membrane CD166 correlated to nodal metastasis and cytoplasmic CD166 correlated to TNM stage, and disease-free survival. The membrane CD166, cytoplasmic CD166 and soluble CD166 showed great potential to be used as a panel of markers for predicting cancer overall survival. We might conclude that CD166 functions as a risk factor for cancers, and the alterations of its different functional isoforms were observed to correlate with specific or interplayed clinical outcomes.

引言：诸多基础研究已为CD166与癌症的相关性提供了一定证据。然而，随着癌症领域中CD166临床价值相关研究的日益增多，相关研究得出了一些存在争议且尚无定论的结果。
综述范围：本研究通过检索PubMed与EMBASE数据库，对已发表的相关文献进行了合理筛选与收集；随后采用荟萃分析（meta-analysis）对CD166相关表达与癌症的关联进行了系统的定量总结，以明确其作为癌症生物标志物进行转化应用的临床意义。
专家评述：整体分析结果显示，总CD166表达与癌症风险相关；膜型CD166与淋巴结转移相关；胞质CD166则与TNM分期及无病生存期相关。膜型CD166、胞质CD166与可溶性CD166具备作为联合标志物预测癌症总生存期的巨大潜力。综上可认为，CD166可作为癌症的风险因子，且其不同功能亚型的表达改变与特定或相互关联的临床结局存在相关性。